Lextrasa (Mesalazine)

Mesalazine acts locally on the intestinal lining, inhibiting cyclooxygenase and lipoxygenase enzymes. This reduces the production of prostaglandins and leukotrienes, leading to decreased inflammatory cytokine release and less mucosal inflammation.

The specific dose of Lextrasa is determined by the prescribing clinician based on the patient’s disease severity, location, and response to therapy. Dosage adjustments are made according to individual clinical needs.

Safety data for mesalazine in pregnancy and lactation are limited. Prescribers should weigh potential benefits against risks and consider alternative therapies if appropriate. Women should discuss use with their healthcare provider.

To request Lextrasa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lextrasa (mesalazine) belongs to the aminosalicylate class, offering a topical anti‑inflammatory effect in the gut. Compared with systemic steroids or biologics, it has a more favorable safety profile but may be less potent for severe disease, making it suitable for mild to moderate cases or maintenance therapy.

Lextrasa should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat to maintain product stability.

Lextrasa is taken orally, usually with water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include severe allergic reactions such as anaphylaxis, blood dyscrasias like leukopenia, liver injury, pancreatitis, and renal impairment. Patients should seek immediate medical attention if they experience symptoms such as rash, fever, jaundice, abdominal pain, or changes in urine output.

Lextrasa should be avoided in individuals with known hypersensitivity to mesalazine, sulfonamides, or any component of the formulation. It is also contraindicated in patients with severe renal or hepatic impairment unless closely monitored by a specialist.